TY - JOUR
T1 - Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
AU - Munoz-Price, L. Silvia
AU - Poirel, Laurent
AU - Bonomo, Robert A.
AU - Schwaber, Mitchell J.
AU - Daikos, George L.
AU - Cormican, Martin
AU - Cornaglia, Giuseppe
AU - Garau, Javier
AU - Gniadkowski, Marek
AU - Hayden, Mary K.
AU - Kumarasamy, Karthikeyan
AU - Livermore, David M.
AU - Maya, Juan J.
AU - Nordmann, Patrice
AU - Patel, Jean B.
AU - Paterson, David L.
AU - Pitout, Johann
AU - Villegas, Maria Virginia
AU - Wang, Hui
AU - Woodford, Neil
AU - Quinn, John P.
N1 - Funding Information:
LSM-P has received speaking fees from Sage and Steris. LP and PN have received research funds from Merck. MG's work was partially financed by the grant Narodowy Program Ochrony Antybiotykow (NPOA) from the Polish Ministry of Health, and the grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education. DML has shareholdings in Dechra, Eco Animal Health, Merck, and Pfizer; has accepted grants, speaking invitations, and conference invitations from Pfizer, Novartis, AstraZeneca, and Astellas; and has advisory or consultancy relationships with Achaogen, AstraZeneca, Basilea, Bayer, Cubist, Curetis, Discuva, GlaxoSmithKline, Kalidex, McKinsey, Meiji, Pfizer, Roche, Tetraphase, Theravance, and Wockhardt. JP has received research funds from Merck and AstraZeneca. MVV has received research grants from Merck Sharp & Dohme, Pfizer SA, Janssen-Cilag SA, Novartis, Merck Colombia, AstraZeneca Colombia SA, bioMerieux Colombia SAS, and Colciencias. JPQ is an employee and potential shareholder in AstraZeneca. All other authors declare that they have no conflicts of interest.
PY - 2013/9
Y1 - 2013/9
N2 - Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.
AB - Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.
UR - http://www.scopus.com/inward/record.url?scp=84882712084&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(13)70190-7
DO - 10.1016/S1473-3099(13)70190-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 23969216
AN - SCOPUS:84882712084
SN - 1473-3099
VL - 13
SP - 785
EP - 796
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 9
ER -
